亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study

肝细胞癌 全身疗法 医学 多中心研究 内科学 肿瘤科 肝衰竭 抢救疗法 癌症 随机对照试验 乳腺癌
作者
J. Yi,Zhijian Zhu,Gong‐Wei Liu,Yi‐Min Zhang,Jie Xu,Xin‐Tong Wu,Ke Ding,Jianchao Liu,Ke‐Fei Zhang,Xiong‐Ying Jiang,Qifeng Chen,Yue Hu,Song Chen,Sui‐Xing Zhong,J.J. Wang,Ning Lyu,Ming Zhao
出处
期刊:Hepatology Research [Wiley]
卷期号:54 (6): 575-587 被引量:4
标识
DOI:10.1111/hepr.14007
摘要

Abstract Aim The study was conducted to evaluate the feasibility and safety profile of hepatic arterial infusion chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin (HAIC‐FOLFOX) as an alternative therapeutic choice for patients with advanced hepatocellular carcinoma (HCC) that is refractory to systemic treatment including immune checkpoint blockades or molecular targeting agents. Methods Two hundred and forty five consecutive patients with advanced HCC who received HAIC‐FOLFOX treatment after systemic treatment failure were retrospectively reviewed in six institutions and their survival, tumor response, and tolerance were assessed. Results The median overall survival (OS) and progression‐free survival of the 209 included participants were 10.5 months (95% confidence interval [CI], 8.1–12.9) and 6.0 months (95% CI, 5.1–6.9), respectively. According to Response Evaluation Criteria in Solid Tumors 1.1 criteria, the objective response rate was 21.1%, and the disease control rate was 64.6%. Multivariate analysis of risk factors of OS were albumin–bilirubin grade (2 and 3 vs. 1, hazard ratio [HR] 1.57; 95% CI, 1.05–2.34; p = 0.028), tumor number (>3 vs. 1–3, HR 2.18; 95% CI, 1.10–4.34; p = 0.026), extrahepatic spread (present vs. absent, HR 1.61, 95% CI, 1.06–2.45; p = 0.027), synchronous systemic treatment (present vs. absent, HR 0.55, 95% CI, 0.37–0.83; p = 0.004) and treatment response (responder vs. nonresponder, HR 0.30, 95% CI, 0.17–0.53; p < 0.001). Grade 3–4 adverse events (AEs) occurred in 59 (28.2%) HCC patients. All AEs were manageable, and deaths related to hepatic artery infusion chemotherapy treatment were not observed. Conclusions Our findings support the effectiveness and safety of HAIC‐FOLFOX treatment for patients with advanced HCC who have failed systemic treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CPU完成签到 ,获得积分10
10秒前
传奇3应助江蹇采纳,获得10
21秒前
35秒前
jj发布了新的文献求助10
40秒前
快乐的素完成签到 ,获得积分10
43秒前
科研通AI6.1应助jj采纳,获得10
46秒前
1分钟前
1分钟前
1分钟前
Owen应助科研通管家采纳,获得30
1分钟前
领导范儿应助科研通管家采纳,获得10
1分钟前
任性傲珊发布了新的文献求助10
1分钟前
cly完成签到 ,获得积分10
1分钟前
赘婿应助wenwen0666采纳,获得50
1分钟前
2分钟前
南栀倾寒发布了新的文献求助10
2分钟前
Ava应助zhang采纳,获得30
2分钟前
2分钟前
2分钟前
2分钟前
zhang发布了新的文献求助30
2分钟前
2分钟前
zhang完成签到,获得积分20
2分钟前
3分钟前
wenwen0666发布了新的文献求助50
3分钟前
大象完成签到 ,获得积分10
3分钟前
attention完成签到,获得积分10
3分钟前
Sweety-完成签到 ,获得积分10
3分钟前
慕青应助科研通管家采纳,获得10
3分钟前
小蘑菇应助科研通管家采纳,获得10
3分钟前
TT完成签到,获得积分10
3分钟前
3分钟前
4分钟前
corleeang完成签到 ,获得积分10
4分钟前
vvan发布了新的文献求助10
4分钟前
zhiji发布了新的文献求助10
4分钟前
kbcbwb2002完成签到,获得积分0
4分钟前
Iris3013完成签到 ,获得积分10
4分钟前
4分钟前
Yini应助OsamaKareem采纳,获得14
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1500
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Quality by Design - An Indispensable Approach to Accelerate Biopharmaceutical Product Development 800
Pulse width control of a 3-phase inverter with non sinusoidal phase voltages 777
Signals, Systems, and Signal Processing 610
Research Methods for Applied Linguistics: A Practical Guide 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6399245
求助须知:如何正确求助?哪些是违规求助? 8214951
关于积分的说明 17407491
捐赠科研通 5452566
什么是DOI,文献DOI怎么找? 2881820
邀请新用户注册赠送积分活动 1858293
关于科研通互助平台的介绍 1700290